Abstract
The carbonic anhydrase (CA) enzyme family consists of thirteen active isozymes in mammals. The most recently characterized members of this family are cytosolic CA XIII and membrane-bound CA XV. This article describes recent advances in the CA family, especially CA XIII and XV. We have also included catalytic activity data on human CA XIII and mouse CA XV. Additionally, the inhibition constants of acetazolamide toward these isozymes were determined to be kcat = 1.5 x 105 s-1, kcat/KM = 1.1 x 107 M-1s-1 and KI = 16 nM for human CA XIII and kcat= 4.7 x 105 s-1, kcat/KM = 3.3 x 107 M-1s-1 and KI = 72 nM for mouse CA XV. Although the activity of CA XIII is the second lowest reported thus far for any of the human CAs, it may have a role in maintaining the acid-base balance in the kidney and the gastrointestinal and reproductive tracts. CA XV is an exceptional enzyme, as it seems to be active in numerous species, such as rodents, birds and fish, but is absent from humans and chimpanzees. Mouse CA XV is a moderately active enzyme, suggesting that it may play a physiological role at least in the kidney. It is likely that other isozymes have substituted for this protein in humans. In addition to the novel data on CA XIII and XV, we present the catalytic activities as well as inhibition constants of acetazolamide for all mammalian CA isozymes in this review.
Keywords: inhibition, catalytic activity, expression, characterization, carbonic anhydrase XV, Carbonic anhydrase XII
Current Pharmaceutical Design
Title: Recent Advances in Research on the Most Novel Carbonic Anhydrases,CA XIII and XV
Volume: 14 Issue: 7
Author(s): S. Parkkila, C. T. Supuran, A. Innocenti, S. M. Monti, G. De Simone and M. Hilvo
Affiliation:
Keywords: inhibition, catalytic activity, expression, characterization, carbonic anhydrase XV, Carbonic anhydrase XII
Abstract: The carbonic anhydrase (CA) enzyme family consists of thirteen active isozymes in mammals. The most recently characterized members of this family are cytosolic CA XIII and membrane-bound CA XV. This article describes recent advances in the CA family, especially CA XIII and XV. We have also included catalytic activity data on human CA XIII and mouse CA XV. Additionally, the inhibition constants of acetazolamide toward these isozymes were determined to be kcat = 1.5 x 105 s-1, kcat/KM = 1.1 x 107 M-1s-1 and KI = 16 nM for human CA XIII and kcat= 4.7 x 105 s-1, kcat/KM = 3.3 x 107 M-1s-1 and KI = 72 nM for mouse CA XV. Although the activity of CA XIII is the second lowest reported thus far for any of the human CAs, it may have a role in maintaining the acid-base balance in the kidney and the gastrointestinal and reproductive tracts. CA XV is an exceptional enzyme, as it seems to be active in numerous species, such as rodents, birds and fish, but is absent from humans and chimpanzees. Mouse CA XV is a moderately active enzyme, suggesting that it may play a physiological role at least in the kidney. It is likely that other isozymes have substituted for this protein in humans. In addition to the novel data on CA XIII and XV, we present the catalytic activities as well as inhibition constants of acetazolamide for all mammalian CA isozymes in this review.
Export Options
About this article
Cite this article as:
Parkkila S., Supuran T. C., Innocenti A., Monti M. S., Simone De G. and Hilvo M., Recent Advances in Research on the Most Novel Carbonic Anhydrases,CA XIII and XV, Current Pharmaceutical Design 2008; 14 (7) . https://dx.doi.org/10.2174/138161208783877811
DOI https://dx.doi.org/10.2174/138161208783877811 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Coumarins as Inhibitors of HIV Reverse Transcriptase
Current HIV Research Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Enterobacteriaceae that Produce Extended-spectrum β -lactamases and AmpC β -lactamases in the Community: The Tip of the Iceberg?
Current Pharmaceutical Design Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Cerebrovascular Amyloidosis and Dementia
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Genetically Engineered Stem Cells for Therapeutic Gene Delivery
Current Gene Therapy Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology Severe Meningococcal Infections in Children and Adolescents
Current Pediatric Reviews In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Regulatory Circuitries Coordinated by Transcription Factors and microRNAs at the Cornerstone of Hematopoietic Stem Cell Self-Renewal and Differentiation
Current Stem Cell Research & Therapy Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
Current Cancer Drug Targets Tuberculosis Treated by Multiple Drugs: An Overview
Current Drug Delivery Crystal Structure and Interaction of Phycocyanin with β-Secretase: A Putative Therapy for Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Neuro-AIDS: Current Status and Challenges to Antiretroviral Drug Therapy (ART) for Its Treatment
Current Drug Therapy